Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05347342

A Diagnostic for the Early Detection of Bladder Cancer

To improve upon the non-invasive detection of bladder cancer by further validating a multiplex ELISA assay directed at a bladder cancer-associated diagnostic signature in voided urine samples of patients with a high risk of developing bladder cancer.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Long Beach VA Healthcare System, Long Beach, California, United States

Loading trial locations.

About this study

Environmental exposures, specifically tobacco smoke, increases the risk of many cancers, including bladder cancer. To date, there are no diagnostics capable of detecting bladder cancer early, that is prior to clinical presentation. Because of this severe limitation, nearly 30% of patients initially present with stage 2 and higher bladder cancer. Stage 2 bladder cancer has a 5-year survival of 50%, while stage 3/4 have a 5-year survival of <20%. Ideally, bladder cancer would be preventable. Unfortunate, this has not come to fruition. If these stage 2-4 bladder cancer cases could be detected at Stage 1 (5-yr survival >94%), then its possible to see an improvement in bladder cancer survival rates (21-23).

in this study, a urine-based diagnostic that possesses the potential to accurately identify patients who harbor bladder cancer prior to clinical manifestation will be tested.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants must be:

  • Age 50 years or older
  • >20 pack year history of tobacco exposure
  • Free of any malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years. Patients with localized prostate cancer who are being followed by an active surveillance program are also eligible.
  • Scheduled to be evaluated in the Pulmonary Rehab Clinic or Lung Cancer Screening Clinic
  • Willing and able to give written informed consent
  • Willing to provide voided urine sample
  • Be able and willing to complete semi-annual research clinic visits for 4 years

Exclusion criteria

Participants must not have:

  • History of hematuria (microscopic or gross) within 2 years of signing consent.
  • Previous history of bladder cancer
  • A known active urinary tract infection or urinary retention
  • An active stone disease (renal or bladder) or renal insufficiency (creatinine >2.0 mg/dL) - Serum creatinine value can be up to 2 years before consent, otherwise repeat.
  • An ureteral stents, nephrostomy tubes or bowel interposition
  • A recent genitourinary instrumentation (within 7 days prior to collection of voided urine sample)

Treatment and study plan

Primary outcomes

  1. 1. To assess the ability to recruit and retain an appropriate high-risk group of subjects into a 4-year longitudinal study monitoring them for the development of bladder cancer.

    Time frame: 5 years

    Ability to recruit

  2. 2. To report the sensitivity and specificity of the multiplex immunoassay ability to detect bladder cancer in patients with high risk of developing bladder cancer: >50 years and >40 pack year history of tobacco exposure.

    Time frame: 5 years

    Performance of multiplex test in this study

  3. 3. To develop a prediction risk calculator from this cohort using cutting edge machine learning techniques (e.g., random forest) incorporating biomarker data and clinical data.

    Time frame: 5 years

    Development of a risk calculator

Sponsors and collaborators

Lead sponsor

Cedars-Sinai Medical Center

Other

Collaborators

  • National Cancer Institute (NCI)
  • Nonagen Bioscience Corporation
  • VA Long Beach Healthcare System

Registry information

Official study title

A Novel Multiplex Immunoassay for the Early Detection of Bladder Cancer

Important dates

Study start
2022
Primary completion
2029
Study completion
2029
First posted
Apr 26, 2022
Registry last updated
Feb 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.